The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
NCT Number: NCT01934855
The main goal of this research is to characterize patient-specific respiration-induced tumor and surrogate motion to evaluate the accuracy and effectiveness of the surrogate-based motion management strategies currently used in clinics. Specifically, the investigators hypothesize that dynamic MRI (Magnetic Resonance Imaging) obtained over a temporal duration consistent with radiotherapy treatments will provide spatio-temporal information of both the tumor and surrogate, and therefore can serve as a means to assess the quality of the tumor motion tracking with the surrogate. To test this hypothesis, the investigators specifically propose to 1) track and characterize the tumor and surrogate motion with 4D (4 dimensional)-MRI and 2) evaluate surrogate-based motion tracking in a cohort of patients with thoracic tumors.
External and internal surrogate-based strategies commonly used in clinics have not been appropriately validated. With the increasing adaptation of these surrogate methods for motion management, the proposed research addresses these urgent issues in clinical radiotherapy while providing a means to achieve patient-specific motion management.
Looking for future studies?
Notify MeRespiration-induced patient motion has become a major obstacle for achieving high-precision radiotherapy of cancers especially in the thorax and upper abdomen. As the target is continuously moving, an additional margin has to be added to the clinical target volume to compensate for the uncertainty in the tumor and organ motion, causing toxicity to the normal tissue and limiting the dose delivered to the target. To account for the tumor motion, surrogate tracking methods are commonly used in clinics during radiotherapy. However, the relationship between the surrogate and tumor motion is hard to generalize as it depends on individual patients, tumor location, treatment fractions, and sometimes shows complex patterns or transient, unpredictable changes. Hence, there is an urgent need to better scrutinize the current surrogate-based motion management strategies. Moreover, the most robust motion management strategy for the given patient should be determined in the pre-treatment setting but the investigators currently lack a sufficient tool to provide this information.
4D-CT is typically used to characterize the tumor motion over the course of the radiotherapy. However, 4D-CT is an oversimplified snapshot representation of a single-breathing cycle with low soft tissue contrast while imparting a considerable amount of radiation dose to the patient. Consequently, the limitations of 4D-CT prevent applicability in acquiring information over timescales that represent a treatment session. MRI is highly advantageous as it is non-ionizing and provides excellent soft tissue contrast. Although real-time 3D dynamic MRI is limited by low image quality and temporal resolution, 2D dynamic MRI techniques have high fidelity and spatio-temporal resolution requisite for real-time tracking of the moving target. Furthermore, a respiration-correlated 4D-MRI can be reconstructed from multi-slice 2D dynamic MR images, enabling volumetric image processing and analysis. Therefore, 4D-MRI is an attractive solution to address breathing motion and tumor tracking obstacles in radiotherapy.
The main goal of this research is to characterize patient-specific respiration-induced tumor and surrogate motion to evaluate the accuracy and effectiveness of the surrogate-based motion management strategies currently used in clinics. Specifically, the investigators hypothesize that dynamic MRI obtained over a temporal duration consistent with radiotherapy treatments will provide spatio-temporal information of both the tumor and surrogate, and therefore can serve as a means to assess the quality of the tumor motion tracking with the surrogate. To test their hypothesis, the investigators specifically propose to 1) track and characterize the tumor and surrogate motion with 4D-MRI and 2) evaluate surrogate-based motion tracking in a cohort of patients with thoracic tumors.
External and internal surrogate-based strategies commonly used in clinics have not been appropriately validated. With the increasing adaptation of these surrogate methods for motion management, the proposed research addresses these urgent issues in clinical radiotherapy while providing a means to achieve patient-specific motion management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
To characterize patient-specific respiration-induced tumor and surrogate motion to evaluate the accuracy and effectiveness of the surrogate-based motion management strategies currently used in radiotherapy.
Time frame: 1 year
Tumor and surrogate motion will be quantified by measuring the displacements from their end-exhale positions. Since the tumor may deform during motion, we will not only consider the trajectories of the center of mass but also the tumor borders. The tumor position as a function of the surrogate position will be analyzed along each moving direction. Pearson correlation coefficients and the sum of squared residual errors based on a regression analysis will be computed to provide a quantitative measure of the correlation between the surrogate and tumor positions. To measure the tumor deformation, correlations of the motion between the SI borders, AP borders, LR borders will also be computed. Although lung tumor likely does not significantly deform, this analysis will be useful for tumors that may deform significantly during motion. The motion under the different breathing patterns will be analyzed separately, and compared to each other.
Time frame: 1 year
Respiratory gating is one predominant technique for managing respiratory motion. Gating attempts to minimize normal tissue dose by delivering radiation during a portion of the respiratory cycle where the respiratory state is typically determined from an external surrogate as an optical signal. We will use different gating boundaries, e.g. 10%, 20% of the surrogate motion range (from mean exhale to mean inhale) on each axes as commonly used in clinical practice. Sensitivity and specificity of the gating will be computed by comparing the portion of time the surrogate is below/above the gating boundary and that the tumor is below/above the gating boundary.
Time frame: 1 year
MRI scans of the patient will be acquired pre- and intra-treatment. Tumor motion variability will be computed between these two scans. We will evaluate the correlation of the target location captured at different time points by computing target volume overlap and systematic volume shift. We will also analyze the tumor position as a function of the surrogate position for both pre- and intra-treatment scans, and will investigate how well these two distributions match. To quantitatively measure the differences, we will compute various statistical similarity measures such as correlation coefficient and mutual information. We will also calculate pre-treatment margins to account for the tumor motion using the pre-treatment retrospective 4D-MRI reconstruction, and calculate the portion of treatment time the tumor moves within or outside the specified margins during the successive scans.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06493682
Behavior, Cancer
Amasya, Turkey (Türkiye)
View Trial DetailsNCT05364372
Behavior, Cancer
Tucson, Arizona, United States
View Trial DetailsNCT01445483
Brain Diseases, Brain Metastasis
Bethesda, Maryland, United States
View Trial DetailsNCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial Details